PDCD1 and neoplasm: Sintilimab is an IgG4 monoclonal antibody that specifically binds to the PD-1 molecule on the surface of T cells, thereby inhibiting the PD-1/PD-L1 pathway, which prevents tumor immune tolerance and reactivates the anti-tumor activity of lymphocytes for the purpose of tumor treatment.